Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 99% Improvement Relative Risk Barry et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 605 patients in Saudi Arabia Lower mortality with HCQ (not stat. sig., p=0.6) Barry et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2021.03.058 Favors HCQ Favors control
Clinical Characteristics and Outcomes of Hospitalized COVID-19 Patients in a MERS-CoV Referral Hospital during the Peak of the Pandemic
Barry et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.03.058
Barry et al., Clinical Characteristics and Outcomes of Hospitalized COVID-19 Patients in a MERS-CoV Referral Hospital during.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.03.058
Mar 2021   Source   PDF  
  All Studies   Meta
605 hospitalized patients in Saudi Arabia showing no mortality with HCQ (only 6 patients received HCQ).
risk of death, 98.9% lower, RR 0.01, p = 0.60, treatment 0 of 6 (0.0%), control 91 of 599 (15.2%), NNT 6.6, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Barry et al., 23 Mar 2021, retrospective, Saudi Arabia, peer-reviewed, 14 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: International Journal of Infectious Diseases 106 (2021) 43–51 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: Clinical characteristics and outcomes of hospitalized COVID-19 patients in a MERS-CoV referral hospital during the peak of the pandemic Mazin Barrya,* , Nouf Althabita , Layan Akkielaha , AbdulEllah AlMohayaa,b , Muath Alotaibia , Sara Alhasania , Abdulwahab Aldreesa , Abdulaziz AlRajhia , Ali AlHijia , Fahad Almajida , Aynaa AlSharidia , Fatimah S. Al-Shahrania , Naif H. Alotaibia , Abdulkarim AlHetheelc a b c Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia Internal Medicine Department, Ad-Dariya Hospital, Ministry of Health, Riyadh, Saudi Arabia Microbiology Unit, Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia A R T I C L E I N F O A B S T R A C T Article history: Received 8 January 2021 Received in revised form 16 March 2021 Accepted 18 March 2021 Objective: To describe the clinical characteristics and outcomes of hospitalized coronavirus disease 2019 (COVID-19) patients in a middle east respiratory syndrome coronavirus (MERS-CoV) referral hospital during the peak months of the pandemic. Design: A single-center case series of hospitalized individuals with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in King Saud University Medical City (KSUMC), an academic tertiary care hospital in Riyadh, Saudi Arabia. Clinical and biochemical markers were documented. Risks for ventilatory support, intensive care unit (ICU) admission and death are presented. Results: Out of 12,688 individuals tested for SARS-CoV-2 by real time reverse transcriptase polymerase reaction (RT-PCR) from June 1 to August 31, 2020, 2,683 (21%) were positive for COVID-19. Of the latter, 605 (22%) patients required hospitalization with a median age of 55, 368 (61%) were male. The most common comorbidities were hypertension (43%) and diabetes (42%). Most patients presented with fever (66%), dyspnea (65%), cough (61%), elevated IL-6 (93.5%), D-dimer (90.1%), CRP (86.1%), and lymphopenia (41.7%). No MERS-CoV co-infection was detected. Overall, 91 patients (15%) died; risk factors associated with mortality were an age of 65 years or older OR 2.29 [95%CI 1.43–3.67], presence of two or more comorbidities OR 3.17 [95%CI 2.00–5.02], symptoms duration of seven days or less OR 3.189 [95%CI (1.64 – 6.19]) lymphopenia OR 3.388 [95%CI 2.10–5.44], high CRP OR 2.85 [95%CI 1.1–7.32], high AST OR 2.95 [95% CI 1.77–4.90], high creatinine OR 3.71 [95%CI 2.30–5.99], and high troponin-I OR 2.84 [95%CI 1.33–6.05]. Conclusion: There is a significant increase in severe cases of COVID-19. Mortality was associated with older age, shorter symptom duration, high CRP, low lymphocyte count, and end-organ damage. © 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( Keywords: COVID-19 SARS-CoV-2 MERS-CoV Mortality
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop